SP
Pagano, Sabrina
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Autoimmunity in MASLD : Focus on autoantibodies, anti‐apolipoprotein A1 IgG and G protein‐coupled receptors | European journal of clinical investigation |  | 2025 | 78 | 313 | ||
| Autoantibodies against apolipoprotein A-1 and cadmium : possible links tocardiovascular and liver diseases across multiple models | ESC (European Society of Cardiology) Congress 2025 | 2025 | 10 | 0 | |||
| Autoantibodies against apolipoprotein A-1 and cadmium : Possible links tocardiovascular and liver diseases across multiple models | 93rd EAS (European Atherosclerosis Society) Congress | 2025 | 13 | 0 | |||
| Geospatial clustering of autoantibodies against apolipoprotein A-1 andenvironmental pollution in the Geneva general population | 93rd EAS (European Atherosclerosis Society) Congress | 2025 | 16 | 0 | |||
| Association between SARS-CoV-2 infection and anti-apolipoprotein A-1 antibody in children | Frontiers in immunology | | 2025 | 58 | 109 | ||
| Autoantibodies to apolipoprotein A-I in hepatitis C virus infection : a role in disease progression? | Frontiers in immunology | | 2025 | 38 | 43 | ||
| Faux positif lié à une macrotroponinémie élevée | Revue médicale suisse | | 2024 | 117 | 41 | ||
| Anti-Apolipoprotein A-1 IgG, incident cardiovascular events and lipid paradox inrheumatoid arthritis | ESC (Europan Society of Cardiology) Congress 2024 | 2024 | 7 | 0 | |||
| People living with HIV display increased anti-apolipoprotein A1 auto-antibodies, inflammation, and kynurenine metabolites : a case–control study | Frontiers in cardiovascular medicine | | 2024 | 117 | 47 | ||
| Anti-apolipoprotein A-1 IgG, incident cardiovascular events and lipid paradox in rheumatoid arthritis | 92nd EAS (European Atherosclerosis Society) Congress | 2024 | 10 | 0 | |||
| Anti-apolipoprotein A-1 IgG, incident cardiovascular events, and lipid paradox in rheumatoid arthritis | Frontiers in cardiovascular medicine | | 2024 | 120 | 209 | ||
| Linking antibody against apolipoprotein A-1 to nonalcoholic steatohepatitis in mice | 92nd EAS (European Atherosclerosis Society) Congress | 2024 | 9 | 0 | |||
| Linking antibody against apolipoprotein A-1 to metabolic dysfunction-associatedsteatohepatitis in mice | ESC (Europan Society of Cardiology) Congress 2024 | 2024 | 7 | 0 | |||
| Associations between high-density lipoprotein particle’s proteome, subfractions and autoantibodies against apolipoprotein A1 in HIV patients | 92nd EAS (European Atherosclerosis Society) Congress | 2024 | 10 | 0 | |||
| Geospatial clustering of auto-antibodies against apolipoprotein A-1, heavy metals,cardiovascular and liver diseases in the general population | ESC (Europan Society of Cardiology) Congress 2024 | 2024 | 12 | 0 | |||
| Linking Antibodies Against Apolipoprotein A-1 to Metabolic Dysfunction-Associated Steatohepatitis in Mice | International journal of molecular sciences | | 2024 | 128 | 158 | ||
| Geospatial clustering of auto-antibodies against apolipoprotein A-1, heavy metals, cardiovascular and liver diseases in the general population | 92nd EAS (European Atherosclerosis Society) Congress | 2024 | 12 | 0 | |||
| Antibody against apolipoprotein-A1, Metabolic-Associated Fatty Liver Diseaseand cardiovascular risk : a translational study | ESC (European Society of Cardiology) Congress 2023 | 2023 | 6 | 0 | |||
| Comment on: Humoral responses against HDL are linked to lipoprotein traits, atherosclerosis, inflammation and pathogenic pathways during early arthritis stages | Rheumatology |  | 2023 | 86 | 0 | ||
| Association of Trace Element Levels with Outcomes in Critically Ill COVID-19 Patients | Nutrients | | 2023 | 701 | 760 | ||
| Antibody against apolipoprotein-A1, non-alcoholic fatty liver disease and cardiovascular risk: a translational study | Journal of translational medicine | | 2023 | 143 | 158 | ||
| Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseases | Frontiers in immunology | | 2023 | 132 | 90 | ||
| Serum Level of Cytokeratin 18 (M65) as a Prognostic Marker of High Cardiovascular Disease Risk in Individuals with Non-Alcoholic Fatty Liver Disease | Biomolecules | | 2023 | 77 | 197 | ||
| Anti‐SARS-CoV‐2 mRNA vaccines as inducers of humoral response against apolipoprotein A‐1? | European journal of clinical investigation | | 2022 | 248 | 146 | ||
| GPR55 in B cells limits atherosclerosis development and regulates plasma cell maturation | Nature cardiovascular research | | 2022 | 220 | 56 | ||
| High antibody titers against apolipoprotein-A1 in NAFLD: a possible link between fatty liver disease and CVD? | 90th European Atherosclerosis Society (EAS) congress | 2022 | 163 | 0 | |||
| Transient elevation of humoral responses against apolipoprotein A-1 following COVID-19 and its association with symptoms persistence | 90th EAS (European Atherosclerosis Society) Congress | 2022 | 98 | 0 | |||
| Bariatric Surgery Leads to a Reduction in Antibodies to Apolipoprotein A-1: a Prospective Cohort Study | Obesity surgery | | 2022 | 369 | 161 | ||
| Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistence | European journal of clinical investigation | | 2022 | 449 | 171 | ||
| Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA | RMD open | | 2022 | 122 | 104 | ||
| Kinetics of inflammatory biomarkers to predict one-year mortality in older patients hospitalized for pneumonia: a multivariable analysis | International journal of infectious diseases | | 2022 | 215 | 253 | ||
| SARS-COV2- infection as a trigger of humoral response against apolipoprotein A-1 | EAS Congress 2021 | 2021 | 384 | 38 | |||
| Anti‐ApoA‐1 IgGs predict resistance to waist circumference reduction after Mediterranean diet | European journal of clinical investigation | | 2021 | 207 | 0 | ||
| Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses | The Lancet. Rheumatology | | 2021 | 245 | 203 | ||
| SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1 | European Journal of Clinical Investigation | | 2021 | 424 | 271 | ||
| Role of Clinical Characteristics and Biomarkers at Admission to Predict One-Year Mortality in Elderly Patients with Pneumonia | Journal of clinical medicine | | 2021 | 271 | 209 | ||
| Autoantibodies directed against apolipoprotein-A1 as a potential contributor to Non-Alcoholic Fatty Liver Disease | 89th Europen Society of Atherosclerosis (EAS) | 2021 | 147 | 0 | |||
| Antibodies against apolipoprotein a-1 as disruptors of cellular cholesterol homeostasis promoting foam cell formation | 88th EAS (European Atherosclerosis Society) Congress | 2020 | 69 | 0 | |||
| Antiapolipoprotein A-1 Autoantibody Positivity Is Associated with Threatened Abortion | BioMed research international | | 2020 | 181 | 135 | ||
| Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma | PLOS ONE | | 2020 | 470 | 354 | ||
| Auto-antibodies against apolipoprotein a-1 block cancer cells proliferation and induce apoptosis | Oncotarget | | 2020 | 174 | 133 | ||
| Atherosclerotic plaque vulnerability is increased in mouse model of lupus | Scientific Reports | | 2020 | 326 | 240 | ||
| Prognostic and therapeutic considerations of antibodies against c‐ter apolipoprotein A‐1 in the general population | Clinical & translational immunology | | 2020 | 209 | 166 | ||
| C-terminus apoa-1 mimetic peptides to detect cognate auto-antibodies and reverse HIV-induced foam cell formation | Atherosclerosis | | 2020 | 254 | 0 | ||
| Antibodies against the C-terminus of apoA-1 are inversely associated with cholesterol efflux capacity and HDL metabolism in subjects with and without type 2 diabetes mellitus | International Journal of Molecular Sciences | | 2019 | 393 | 226 | ||
| Autoantibodies to apolipoprotein A-1 as independent predictors of cardiovascular mortality in renal transplant recipients | Journal of Clinical Medicine | | 2019 | 348 | 166 | ||
| Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects | Journal of clinical medicine | | 2019 | 243 | 113 | ||
| Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naïve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort | Atherosclerosis | | 2019 | 439 | 1 | ||
| Non-linear relationship between anti-apolipoprotein A-1 IgGs and cardiovascular outcomes in patients with acute coronary syndromes | Journal of Clinical Medicine | | 2019 | 441 | 209 | ||
| Anti-apolipoprotein A-1 autoantibodies correlate with disease activity in systemic lupus erythematosus | Rheumatology | | 2019 | 482 | 288 | ||
| Anti-ApoA-1 IgGs in Familial Hypercholesterolemia Display Paradoxical Associations with Lipid Profile and Promote Foam Cell Formation | Journal of clinical medicine | | 2019 | 242 | 204 | ||
| P5343 - The presence of anti-apolipoprotein A1 autoantibodies is associated with a pro-atherogenic profile in HIV-infected patients | ESC Congress 2019 together with World Congress of Cardiology | 2019 | 122 | 0 | |||
| Association of novel biomarkers with major clinical outcomes in a cohort of patients with atherosclerotic renovascular disease | Annals of Clinical Biochemistry | | 2019 | 357 | 0 | ||
| ELISA methods comparison for the detection of auto-antibodies against apolipoprotein A1 | Journal of Immunological Methods | | 2019 | 394 | 1 | ||
| Deficiency of monoacylglycerol lipase enhances IgM plasma levels and limits atherogenesis in a CB2-dependent manner | Thrombosis and Haemostasis | | 2019 | 436 | 0 | ||
| Humoral immunity against HDL particle: a new perspective in cardiovascular diseases? | Current Pharmaceutical Design | | 2019 | 277 | 0 | ||
| Infection-induced humoral autoimmunity: a missing link in the interplay between pathogens, dyslipidemia, and innate immunity? | Journal of the American College of Cardiology | | 2018 | 303 | 0 | ||
| Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients | Journal of Infection | | 2018 | 583 | 1 | ||
| Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis? | Hepatology International | | 2018 | 446 | 284 | ||
| Anti-Apolipoprotein A-1 IgG Predict All-Cause Mortality and Are Associated with Fc Receptor-Like 3 Polymorphisms | Frontiers in Immunology | | 2017 | 473 | 248 | ||
| Impact of CD14 Polymorphisms on Anti-Apolipoprotein A-1 IgG-Related Coronary Artery Disease Prediction in the General Population | Arteriosclerosis, Thrombosis, and Vascular Biology | | 2017 | 519 | 0 | ||
| Vitamin D receptor is expressed within human carotid plaques and correlates with pro-inflammatory M1 macrophages | Vascular pharmacology | 2016 | 565 | 0 | |||
| Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population. Results from the CoLaus study | Thrombosis and haemostasis | | 2016 | 567 | 7 | ||
| The Associations of Blood Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin with Progression from CKD to ESRD | Clinical Journal of the American Society of Nephrology | | 2016 | 424 | 0 | ||
| Anti-apolipoprotein A-1 auto-antibodies as active modulators of atherothrombosis | Thrombosis and haemostasis | | 2016 | 772 | 706 | ||
| Diagnostic and prognostic value of autoantibodies anti-apolipoprotein A-1 and anti-phosphorylcholine in acute non-ST elevation myocardial infarction | European journal of clinical investigation | | 2015 | 636 | 3 | ||
| CD14 as a Mediator of the Mineralocorticoid Receptor-Dependent Anti-apolipoprotein A-1 IgG Chronotropic Effect on Cardiomyocytes | Endocrinology | | 2015 | 671 | 1 | ||
| The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the C-Terminal Helix: A New Rationale for Diagnosis and Treatment of Cardiovascular Disease? | PloS one | | 2015 | 563 | 387 | ||
| Treatment with sulphated galactan inhibits macrophage chemotaxis and reduces intraplaque macrophage content in atherosclerotic mice | Vascular pharmacology | | 2015 | 609 | 0 | ||
| Definition of human apolipoprotein A-I epitopes recognized by autoantibodies present in patients with cardiovascular diseases | The Journal of biological chemistry | | 2014 | 769 | 658 | ||
| 18FDG-PET-CT: an imaging biomarker of high-risk carotid plaques. Correlation to symptoms and microembolic signals | Stroke | | 2014 | 716 | 3 | ||
| Anti-apolipoprotein A-1 autoantibodies as biomarker for atherosclerosis burden in patients with periodontitis | Journal of periodontal research | | 2013 | 776 | 1 | ||
| Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy | Thrombosis and haemostasis | | 2013 | 741 | 1 | ||
| Auto-antibodies as Emergent Prognostic Markers and Possible Mediators of Ischemic Cardiovascular Diseases | Clinical reviews in allergy & immunology | | 2013 | 651 | 3 | ||
| Anti-apolipoprotein A-1 IgG levels predict coronary artery calcification in obese but otherwise healthy individuals | Mediators of inflammation | | 2012 | 656 | 310 | ||
| Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex | Journal of internal medicine | | 2012 | 753 | 3 | ||
| Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores? | Arthritis care & research | | 2012 | 700 | 0 | ||
| High prevalence of anti-apolipoprotein/A-1 autoantibodies in maintenance hemodialysis and association with dialysis vintage | Therapeutic apheresis and dialysis | | 2012 | 650 | 0 | ||
| Autoantibodies against apolipoprotein A-1 and phosphorylcholine for diagnosis of non-ST-segment elevation myocardial infarction | Journal of internal medicine | | 2012 | 672 | 2 | ||
| The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques | European heart journal | | 2012 | 748 | 0 | ||
| Receptor activator of NF- κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability | Thrombosis and haemostasis | | 2012 | 798 | 0 | ||
| Antiapolipoprotein A-1 IgG chronotropic effects require nongenomic action of aldosterone on L-type calcium channels | Endocrinology | | 2012 | 713 | 0 | ||
| Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability | European heart journal | | 2011 | 676 | 2 | ||
| Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis | Arthritis and rheumatism | | 2010 | 909 | 3 | ||
| Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction | European heart journal | | 2010 | 710 | 0 |
